Drugs / Alcestobart
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04640545 | May 2020 → Aug 2024 | metastatic melanoma | Nanjing Leads Biolabs Co.,Ltd | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07099430 | Sep 2025 → Oct 2027 expected | melanoma | Nanjing Leads Biolabs Co.,Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05609370 | Jan 2023 → May 2025 overdue | colorectal cancer | BeiGene | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05102006 | Nov 2021 → May 2024 | cancer | Nanjing Leads Biolabs Co.,Ltd | Completed | No outcome recorded |
| Phase 1/2 | NCT03744468 | Nov 2018 → Feb 2025 | head and neck squamous cell carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06010303 | Nov 2023 → May 2025 | esophageal squamous cell carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 2 | NCT05909904 | Aug 2023 → Jun 2025 overdue | head and neck squamous cell carcinoma | BeiGene | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05577702 | Mar 2023 → Dec 2024 | non-small cell lung carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 2 | NCT05635708 | Mar 2023 → Dec 2025 overdue | non-small cell lung carcinoma | BeiGene | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04164199 | Dec 2019 → May 2026 | cancer | BeOne Medicines | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alcestobart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05577702 ↗ |
| Known as | LBL-007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06010303 ↗ |
| Action | Inhibit | “alcestobart (Anti-LAG-3)” NCT03744468 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068199 ↗ |
| Route | Intravenous | “alcestobart 300 mg IV infusion on day 1 of each cycle” NCT03744468 ↗ |